Japanese medical device company Olympus Corporation announced on May 27, 2026, that it has signed a definitive agreement to acquire Israeli medical device manufacturer BioProtect for $270 million. The acquisition is expected to close in the third quarter of 2026, subject to regulatory approvals.
BioProtect, based in Israel, has developed the BioProtect Balloon Implant, a biodegradable balloon that is injected into the space between the prostate and rectum to protect healthy tissue from radiation damage during prostate cancer radiotherapy. The implant is designed to reduce the risk of rectal toxicity and improve treatment outcomes.
Olympus, headquartered in Tokyo, is a global leader in medical technology, particularly in endoscopy and surgical solutions. The company stated that the acquisition will strengthen its oncology portfolio and expand its presence in the urology market. Olympus plans to integrate BioProtect's technology into its existing product lineup for prostate cancer treatment.
Financial details of the deal were confirmed by both companies. BioProtect's implant has received regulatory clearance in several markets, including the United States and Europe. The acquisition reflects a growing trend of large medical device firms acquiring smaller innovators to enhance their product offerings.
